Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...
The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...
